Week 02, 2018pdf, World Health Organization, SouthEast Asia Regional Office

Vol. 22, Week 02, 2018

Published 15 January 2018

Meetings/ Important events:
 Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
 Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018

Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 15 January 2018)
Case classification (number)

4

Pending classification

Discarded non-measles nonrubella cases

Epidemiologicallyconfirmed

India 3


Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a

pop
pop n
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n

Laboratory-confirmed

DPR Korea

Rubel l a

Clinically-confirmed

Bhutan

% s erol ogy

res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory

Mea s l es

Epidemiologicallyconfirmed

Bangladesh

Number of
s erum
s peci mens
recei ved i n
l a bora tory


% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection

%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory

Laboratory-confirmed


Countries

%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
mea s l es
s erum
on
ca s es
i ni tia ted s peci mens
col l ected
w/i n 48
hours of
notifi ca tion

8,148


92

80

6,421

100

100

63

2,688

961

511

230


58

3,700

0

2.37

75

26.66

1.85

221

84

79


166

59

105

46

14

0

0

2

0

160


45

21.47

65

18.79

2.68

105

100

100

105

100


100

99

0

0

0

0

0

105

0

0.42


0.00

0.00

19,433

0

31

5,974

81

87

60

3,078

5,833

0

743

1,998

2,691

5,090

0.21

5

7.04

2.17

2.63

1.36

4,946

47

100

2,468

93

73

27

662

0

0

343

0

342

3,599

0.14

Maldives

63

97

100

63

100

100

70

1

0

0

1

0

59

2

17.26

60

2.93

2.93

Myanmar

1,682

41

89

1,459

99

100

94

1,045

189

63

3

0

349

33

0.68

14

25.22

0.06

Nepal

898

23

89

386

64

190

68

57

25

11

16

0

711

78

2.60

55

3.41

0.59

Sri Lanka

203

98

89

177

90

100

62

1

0

18

1

0

183

0

0.89

23

62.00

0.42

Thailand

2,974

29

86

2,390

58

95

59

1,440

14

549

24

0

854

93

1.32

30.87

0.37

131

100

99

119

100

72

52

0

0

0

5

0

122

4

10.07

0.00

4.13

38,804

32

59

19,728

87

94

59

8,986

7,022

1,152

1,368

2,056

9,276

8,944

0.50

9.20

1.84

Indonesia

Timor-Leste
SEAR
1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases

2

Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases

4

38

A lso includes the cases fro m enhanced measles case-based surveillance.

ND=No data

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 15 January 2018)
Case classification (number)

Bhutan
DPR Korea
India 3

3 732

100

100

92

619

354

96

165

0

Pending classification

Epidemiologicallyconfirmed

87

Discarded non-measles nonrubella cases

Laboratory-confirmed

94

Number of
s erum
s peci mens
recei ved i n
l a bora tory

% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory

Clinically-confirmed

4 298

Rubel l a

% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection

Epidemiologicallyconfirmed

Bangladesh

Mea s l es

%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory

Laboratory-confirmed

Countries

%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
s erum
on
mea s l es
i ni tia ted s peci mens
ca s es
col l ected
w/i n 48
hours of
notifi ca tion

3 064

0

Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
100,000 pop n
100,000 pop n

1.96

80

6.85

55

13.42

0.00

0.00

0.00

149

63

87

127

59

102

47

10

0

0

0

0

60

79

8.05

73

100

100

73

100

100

100

0

0

0

0

0

66

7

0.27

41 350

0

22

9 022

84

83

31

3 649

12 713

0

1 618

7 466

6 989

9 018

0.55

8 065

44

100

5 856

98

84

32

2 837

0

0

1 172

0

2 402

1 652

0.95

Maldives

11

100

100

11

100

0

0

0

0

0

0

0

11

0

3.22

Myanmar

587

0

86

503

100

99

97

194

59

21

10

0

303

0

0.59

1 079

13

82

1

100

0

137

102

31

22

0

772

15

Sri Lanka

339

63

86

291

88

100

68

64

0

48

1

0

226

Thailand

1 431

25

87

1 096

61

99

58

695

15

239

7

0

122

75

91

111

100

95

63

2

0

11

9

57 504

15

42

20 823

90

92

46

8 207

13 243

446

3 004

Indonesia

Nepal

4

5

Timor-Leste
SEAR

12.93

7.18

11.25

4.65

15

0.00

0.00

11

5.33

0.19

2.83

56

9.89

0.81

0

1.09

27

62.00

0.42

415

60

0.64

14.63

0.11

0

100

0

8.25

7 466

14 408

10 831

0.77

1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases

4

A lso includes the cases fro m enhanced measles case-based surveillance.

2

Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases

5

So me Lab data variables no t available.

3

1.06

46

10.73

7.43

11.74

5.61

ND=No data

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
http://www.searo.who.int/topics/immunization/

Vol. 22,
Week 02, 2018

Vaccine Preventable Disease Surveillance Bulletin

Page 2

Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 15 January 2018)
2017 (Onset)

2018 (Onset)
Surveillance Indicators

% with 2 spec., at least
24 hrs apart, w/in 14
days

% with any specimen

26

14

2.74

2.69

98

99

7

0

0

0

0

7

0

0.37

0.00

100

100

7

1

0

3.24

2.83

88

100

0

0

0

0

0

0

0

0.00

0.00

0

0

65

38

17

0

0

0

38,870

0

0

12

35,795 3,063 1,286

>90 Days 3

AFP Rate

Pending

Total

Compatible

4

Vaccine Derived
Poliovirus Cases

AFP Cases

Non-Polio AFP Rate

AFP Rate

Vaccine Derived
Poliovirus Cases

103

India

Wild Poliovirus Cases

1,338

% with any specimen

0
0

Pending

% with 2 spec., at least
24 hrs apart, w/in 14
days

0
0

4

0
0

Wild Poliovirus Cases

Non-Polio AFP Rate

Specim en

>90 Days 3

1

Total

Case Classification

Discarded (Non-polio
AFP)

DPR Korea

Specim en

8

AFP Cases
Bangladesh

2

AFP Rates

1,364

Country

Bhutan

1

Surveillance Indicators
Annualized
AFP Rates 2

Compatible

Case Classification

AFP

Discarded (Non-polio
AFP)

AFP

1.80

1.14

96

99

0

0

0

0

0

0

0

0.00

0.00

0

0

8.87

8.17

86

98

139

0

0

0

0

139

0

0.82

0.00

71

83

Indonesia

1,535

0

0

1

1,322

212

128

2.18

1.88

83

97

0

0

0

0

0

0

0

0.00

0.00

0

0

Maldives

6

0

0

0

4

2

0

6.34

4.23

67

100

0

0

0

0

0

0

0

0.00

0.00

0

0

Myanm ar

378

0

0

0

310

68

3

2.80

2.30

96

100

0

0

0

0

0

0

0

0.00

0.00

0

0

Nepal

341

0

0

0

326

15

2

3.93

3.76

99

100

0

0

0

0

0

0

0

0.00

0.00

0

0

Sri Lanka

70

0

0

0

68

2

2

1.29

1.25

84

100

0

0

0

0

0

0

0

0.00

0.00

0

0

Thailand

183

0

0

0

132

51

28

1.58

1.14

66

92

0

0

0

0

0

0

0

0.00

0.00

0

0

3

0

0

0

1

2

1

0.65

0.22

33

100

0

0

0

0

0

0

0

0.00

0.00

0

0

42,861

0

0

13

7.09

6.52

86

98

146

0

0

0

0

146

0

0.63

0.00

73

84

Tim or-Leste
SEAR

39,368 3,480 1,481

1

All countries are using the virologic classification scheme.

2

AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).

3

90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.

Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 15 January 2018)

3

0

0

1

0

0

20

0

8

0

0

0

0

7

5

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

DPR Korea

NPL, Pyongyong

India

Indonesia

7
days

0

0

0

0

0

0

0

0

0

0

0

0

0

0

BJMC, Ahmedabad

258

0

78

0

25

0

0

74

80

1

0

0

0

0

231

0

78

0

0

0

0

67

76

7

0

0

3

0

NIV, Bengaluru

225

0

56

0

24

0

0

67

70

6

2

0

0

0

151

0

57

0

0

0

0

35

45

14

0

0

0

0

ERC, Mumbai

172

0

53

0

13

0

0

52

43

11

0

0

0

0

154

0

52

0

0

0

0

45

36

21

0

0

0

0

SGPGI, Lucknow

311

0

56

0

53

0

0

86

66

16

34

0

0

0

290

0

60

0

0

0

0

100

64

25

41

0

0

0

KIPM, Chennai

98

0

26

0

17

1

0

26

28

0

0

0

0

0

50

0

10

0

0

0

0

27

12

0

0

0

1

0

NCDC, Delhi

231

0

47

0

38

0

0

91

52

3

0

0

0

0

206

0

59

0

0

0

0

88

51

8

0

0

0

0

IoS, Kolkatta

113

0

26

0

18

0

0

35

33

0

1

0

0

0

173

0

54

0

0

0

0

39

58

18

3

0

0

1

CRI, Kasauli

35

0

5

0

7

0

0

11

12

0

0

0

0

0

22

0

11

0

0

0

0

6

5

0

0

0

0

0

India Total

0

Negative

1

0

NEV

0

0

Vaccine
mixture
NPEV by
PCR

0

1

Vaccine

0

0

Wild

0

0

VDPV

3

0

Vaccine

NEV

Negative

0

1

Wild

Vaccine

8

NIH, Bangkok

Vaccine

Wild

IPH, Dhaka

Bhutan

7
Days days

Wild

VDPV

Bangladesh

ITD Labs

Vaccine
mixture
NPEV by
PCR

Vaccine

Results
pending

Wild

Intratypic Differentiation results
Polio 1
Polio 2
Polio 3

Vaccine

AFP cases
referred
for ITD

2017
Results
pending

Wild

Country of
Case

AFP cases
referred
for ITD

2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3

1,443

0

347

0

195

1

0

442

384

37

37

0

0

0

1,277

0

381

0

0

0

0

407

347

93

44

0

4

1

Bio Farma, Bandung

18

0

9

0

3

0

0

1

5

0

0

0

0

0

2

0

0

0

0

0

0

2

0

0

0

0

0

0

NIHRD, Jakarta

12

0

4

0

0

0

0

5

3

0

0

0

0

0

2

0

0

0

0

0

0

0

2

0

0

0

0

0

PHL, Surabaya

13

0

2

0

4

0

0

4

3

0

0

0

0

0

1

0

0

0

0

0

0

1

0

0

0

0

0

0

Indonesia Total

43

0

15

0

7

0

0

10

11

0

0

0

0

0

5

0

0

0

0

0

0

3

2

0

0

0

0

0

Myanm ar

NHL, Yangon

7

0

1

0

1

0

0

2

3

0

0

0

0

0

6

0

1

0

0

0

0

4

1

0

0

0

0

0

Nepal

NIH, Bangkok

6

0

2

0

2

0

0

1

1

0

0

0

0

0

5

0

0

0

0

0

0

3

2

0

0

0

0

0

Sri Lanka

MRI, Colombo

1

0

0

0

0

0

0

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Thailand

NIH, Bangkok

4

0

0

0

0

0

0

2

2

0

0

0

0

0

5

0

2

0

0

0

0

3

0

0

0

0

0

0

1,513

0

368

0

206

1

0

459

404

37

37

1

0

0

1,318

0

392

0

0

0

0

427

357

93

44

0

4

1

TOTAL